Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 863 results for "for merck"

Merck Seeks Expanded Approval of Keytruda Immunotherapy to Treat Lung Cancer

Merck announces encouraging data from pleural mesothelioma study

Merck has announced encouraging data from KEYNOTE-028 study, investigating the use of KEYTRUDA, its anti- programmed cell death protein 1, or PD-1, therapy, in 25 patients with advanced pleural mesothelioma. The early findings presented showed an ..., 1 day ago

998 images for for merck

African Business Review, 1 day ago
Healthcare Global, 2 days ago
Jutia Group, 21 hours ago
Pharmafocus, 3 days ago
West Australian, 4 days ago
Reuters UK, 4 days ago
Pharma Letter, 5 days ago
4 Traders, 4 days ago
Bio Spectrum Asia, 1 week ago
Njbiz, 6 days ago

Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog

Merck & Co. Inc.MRK reported encouraging data from an ongoing pivotal (C-EDGE) phase III program evaluating its once-daily combination regimen - grazoprevir (NS3/4A proteaseinhibitor)/elbasvir (NS5A replication complex inhibitor) - in patients with ...
 Nasdaq23 hours ago Merck's HCV combo shows 99% cure rate in HCV-1 patients with advanced kidney disease  Seeking Alpha2 days ago Merck's HCV combo shows cure rates of 60 - 100% in three genotypes  Seeking Alpha1 day ago

Merck's Hepatitis C Drugs May Challenge Gilead and AbbVie

(Updates with analyst comment in fifth paragraph.) The study also found that among patients who failed other treatments, a combination of Merck's grazoprevir and elbasvir drugs had a cure rate of 92 percent after a 12-week course of therapy. The ...
 Washington Post1 day ago Merck's Hepatitis C Medicines May Challenge Gilead and AbbVie  Bloomberg1 day ago Correction to Merck Hepatitis C Treatment Story Update  Swissquote1 day ago Merck May weekly volatility elevated into Q1 and outlook  Franklin Credit Management Corporation1 day ago

Merck (MRK) Crosses Pivot Point Resistance at $57.89

Shares of Merck (NYSE:MRK) have bullishly opened above the pivot of $57.46 today and have reached the first resistance level of $57.89. Analysts will be watching for a cross of the next upside pivot targets of $58.28
 Individual.com1 day ago Merck (MRK) Approaches New Upside Target of $58.28  Comtex SmarTrend1 day ago Merck (MRK) Breaks Through Resistance at $57.30  Individual.com5 days ago

Potential Merck (MRK) Trade Targets 2.77% Return

The patented options-trade picking algorithms used by found a trading opportunity with Merck & Co Inc. ("MRK) that should provide a 2.77% return in just 56 days. Sell one ...
 Individual.com1 day ago Potential Merck (MRK) Trade Has 5.45% Downside Protection  Individual.com5 days ago Potential Merck (MRK) Trade Has 3.51% Downside Protection  Individual.com1 week ago

Merck Shows EPS Estimates Down In Past Month

Leading up to Merck's announcement of its first-quarter earnings on Tuesday, April 28, 2015 analysts have become more wary as expectations have fallen over the past month to earnings of 75 cents per share from earnings of 77 cents per share. Over ...
 Forbes.com1 day ago

Merck Says Phase 3 C-EDGE Trial Shows High Sustained Virologic Responses

Merck (MRK: Quote), known as MSD outside the U.S. and Canada, announced the first presentations of data from its ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the efficacy and safety of grazoprevir/elbasvir (100mg/50mg) in ...
 RTTNews.com1 day ago Merck Trumpets Successful Trial For Oral Hepatitis C Treatment  Swissquote1 day ago

Merck Presents Hepatitis C Results

We remain bullish as Merck re-emerges as
 TheStreet.com1 day ago

Merck Appoints Udit Batra to Head Combined Life Science Business

Udit Batra, currently CEO and President of Merck Millipore, has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed. The planned US$ ...
 EHealth Magazine1 day ago Udit Batra to head Merck-Sigma Aldrich merger firm  CPhI.cn1 week ago

Merck oral hepatitis C regimen shows 95 pct cure rate

(Reuters) - Merck and Co Inc presented trial results on Friday showing that a once-daily combination of two experimental pills cured 95 percent of previously untreated hepatitis C patients after 12 weeks. The trial included patients infected with ...
 Reuters1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less